Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning
- 939 Downloads
A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1–2 % of lung adenocarcinomas (LADCs) in 2012. Several related clinical trials for non-small cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as cabozantinib, lenvatinib, vandetanib, sunitinib, ponatinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene. Anti-RET activity and the status of clinical development of cabozantinib for KIF5B-RET fusion-positive NSCLC are discussed.
KeywordsCabozantinib KIF5B-RET Lung cancer Non-small cell lung cancer Adenocarcinoma Small-molecule tyrosine kinase inhibitor
This research was supported by Bio & medical technology development program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2014M3A9D9033717).
- Christensen, J.G., H.Y. Zou, M.E. Arango, Q. Li, J.H. Lee, S.R. McDonnell, S. Yamazaki, G.R. Alton, B. Mroczkowski, and G. Los. 2007. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic largecell lymphoma. Molecular Cancer Therapeutics 6: 3314–3322.CrossRefPubMedGoogle Scholar
- ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 02 July 2015.
- Drilon, A., L. Wang, A. Hasanovic, Y. Suehara, D. Lipson, P. Stephens, J. Ross, V. Miller, M. Ginsberg, M.F. Zakowski, M.G. Kris, M. Ladanyi, and N. Rizvi. 2013. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discovery 3: 630–635.PubMedCentralCrossRefPubMedGoogle Scholar
- Drilon AE, Sima CS, Somwar R, Smith R, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG, Rizvi NA. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. Journal of Clinical Oncology 2015; 33: (suppl; abstr 8007).Google Scholar
- Fox, E., B.C. Widemann, M.K. Chuk, L.J. Marcus, A. Aikin, P. Whitcomb, M.J. Merino, M. Lodish, E. Dombi, S.M. Steinberg, S.A. Wells, and F.M. Balis. 2013. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clinical Cancer Research 19: 4239–4248.PubMedCentralCrossRefPubMedGoogle Scholar
- Ju, Y.S., W.-C. Lee, J.-Y. Shin, S. Lee, T. Bleazard, J.K. Won, Y.T. Kim, J.-I. Kim, J.-H. Kang, and J.-S. Seo. 2012. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Research 22: 436–445.PubMedCentralCrossRefPubMedGoogle Scholar
- Kohno, T., H. Ichikawa, Y. Totoki, K. Yasuda, M. Hiramoto, T. Nammo, H. Sakamoto, K. Tsuta, Y. Shimada, R. Iwakawa, H. Ogiwara, T. Oike, M. Enari, A.J. Schetter, H. Okayama, A. Haugen, V. Skaug, S. Chiku, I. Yamanaka, Y. Arai, S.-I. Watanabe, I. Sekine, S. Ogawa, C.C. Harris, H. Tsuda, T. Yoshida, J. Yokota, and T. Shibata. 2012. KIF5B-RET fusion in lung adenocarcinoma. Nature Medicine 18: 375–377.CrossRefPubMedGoogle Scholar
- Kohno, T., K. Tsuta, K. Tsuchihara, T. Nakaoku, K. Yoh, and K. Goto. 2013. RET fusion gene: Translation to personalized lung cancer therapy. Cancer Discovery 104: 1396–1400.Google Scholar
- Lipson, D., M. Capelletti, R. Yelensky, G. Otto, A. Parker, M. Jarosz, J.A. Curran, S. Balasubramanian, T. Bloom, K.W. Brennan, A. Donahue, S.R. Downing, G.M. Frampton, L. Garcia, F. Juhn, K.C. Mitchell, E. White, J. White, Z. Zwirko, T. Peretz, H. Nechushtan, L. Soussan-Gutman, J. Kim, H. Sasaki, H.R. Kim, S.-I. Park, D. Ercan, C.E. Sheehan, J.S. Ross, M.T. Cronin, P.A. Jänne, and P.J. Stephens. 2012. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Medicine 18: 382–384.PubMedCentralCrossRefPubMedGoogle Scholar
- Schoffski P, Elisei R, Muller S. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. Journal of Clinical Oncology 2012; 30: (suppl; abstr 5508).Google Scholar
- Soda, M., Y.L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S.-I. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, and H. Mano. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561–566.CrossRefPubMedGoogle Scholar